- Conditions
- Spinal Muscular Atrophy
- Interventions
- onasemnogene abeparvovec-xioi
- Biological
- Lead sponsor
- Novartis Gene Therapies
- Industry
- Eligibility
- Up to 42 Days
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Aurora, Colorado • Orlando, Florida + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Spinal Muscular Atrophy 1
- Interventions
- Onasemnogene Abeparvovec-xioi
- Biological
- Lead sponsor
- Novartis Gene Therapies
- Industry
- Eligibility
- Not listed
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III, SMA
- Interventions
- Onasemnogene Abeparvovec-xioi
- Biological
- Lead sponsor
- Novartis Gene Therapies
- Industry
- Eligibility
- Not listed
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2035
- U.S. locations
- 18
- States / cities
- Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 14 more
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Onasemnogene Abeparvovec-xioi
- Biological
- Lead sponsor
- Novartis Gene Therapies
- Industry
- Eligibility
- 6 Months to 60 Months
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Stanford, California • Orlando, Florida + 8 more
- Conditions
- Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin
- Interventions
- Apitegromab, Nusinersen, Risdiplam
- Drug
- Lead sponsor
- Scholar Rock, Inc.
- Industry
- Eligibility
- Up to 2 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Orange, California • Palo Alto, California + 9 more
- Conditions
- SMA - Spinal Muscular Atrophy, Gene Therapy
- Interventions
- Onasemnogene Abeparvovec-xioi
- Biological
- Lead sponsor
- Novartis Gene Therapies
- Industry
- Eligibility
- Up to 180 Days
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Stanford, California • Aurora, Colorado + 13 more